Drilldown/Medicines

Nav

Choose a table:

Medicines (732)

Medicines > fda max

: 10 mg/d

or 100 mg/d

or 2.4 g/d

Use the filters below to narrow your results.

None (1) · Alprazolam (1) · Amlodipine (1) · Dapagliflozin (1) · Ezetimibe (1) · Flibanserin (1) · Guaifenesin (1) · Losartan (1) · Sitagliptin (1)

Addyi (1) · Cozaar (1) · Dayvigo (1) · Farxiga (US), Forxiga (international) (1) · Januvia; with metformin Janumet/Janumet XR (1) · Mucinex, Robitussin, Tussin (1) · Norvasc, Katerzia (1) · Xanax (1) · Zetia (1)

None (2) · 5-HT1A agonist, 5-HT2A antagonist, with weaker activity at D4 and other receptors. Net effect involves enhanced prefrontal dopaminergic/noradrenergic tone with decreased serotonergic inhibition of sexual desire. (1) · Competitive antagonist at OX1R and OX2R. Faster receptor association/dissociation kinetics than suvorexant (~16 sec dissociation vs ~57 sec) hypothesized to support sleep onset, with sufficient duration for maintenance. (1) · GABA-A positive allosteric modulator'"`UNIQ--ref-00000067-QINU`"' '"`UNIQ--vote-00000068-QINU`"' (1) · '"`UNIQ--vote-00000073-QINU`"' The long half-life gives smooth, once-daily BP control with low rebound. CYP3A4 substrate; pedal edema is the characteristic, dose-related, non-fluid-overload side effect'"`UNIQ--ref-00000074-QINU`"'. (1) · '"`UNIQ--vote-000000B6-QINU`"' Active metabolite EXP3174 is ~10-40-fold more potent than the parent and accounts for most of the antihypertensive effect; CYP2C9 polymorphism affects conversion'"`UNIQ--ref-000000B7-QINU`"'. (1) · '"`UNIQ--vote-00000762-QINU`"' Largely renally cleared, hence the eGFR-tiered dosing. Rare but well-documented signals: acute pancreatitis (uncertain causal contribution), severe joint pain, and bullous pemphigoid (class effect, especially in older Asian patients)'"`UNIQ--ref-00000763-QINU`"'. (1) · '"`UNIQ--vote-0000104D-QINU`"' Adequate hydration is at least as important as the drug in producing the expectorant effect clinically. Used in combination with dextromethorphan, decongestants, or antihistamines in many proprietary OTC cold preparations. (1)

0.25 mg (1) · 10 mg PO once daily in the morning; 5 mg starting in heart failure (1) · 10 mg PO once daily, with or without food (1) · 100 mg at bedtime daily (1) · 100 mg PO once daily (50 mg if CrCl 30-44; 25 mg if <30 or dialysis) (1) · 2.5-5 mg PO once daily; titrate to 10 mg/d (1) · 200-400 mg PO q4h (IR); 600-1200 mg PO q12h (Mucinex 12-Hour ER) (1) · 5 mg PO at bedtime; may increase to 10 mg if inadequate (1) · 50 mg PO daily (25 mg in volume depletion or hepatic impairment) (1)

0.25 mg, 0.5 mg, 1 mg, 2 mg tablets (immediate-release and orally disintegrating); 0.5 mg, 1 mg, 2 mg, 3 mg extended-release tablets; 1 mg/mL oral concentrate (1) · 10 mg tablet; also as fixed-dose combinations with simvastatin (Vytorin) and atorvastatin (Liptruzet, withdrawn US 2015 but generics exist) (1) · 100 mg tabs (1) · 100, 200, 400 mg IR tablets; 600 mg, 1200 mg Mucinex ER tablets; many liquid formulations and combination products with dextromethorphan, pseudoephedrine, antihistamines (1) · 2.5, 5, 10 mg tablets; 1 mg/mL oral suspension (1) · 25 mg, 50 mg, 100 mg tablets (1) · 25, 50, 100 mg tablets; combination tablets with metformin (1) · 5 mg, 10 mg tablets (2)

Oral (9)

30 minutes (1) · 30-60 min (immediate-release); 1-2 h (extended-release) (1) · BP effect 1-2 weeks; antihypertensive peak 3-6 weeks (1) · BP effect within 24 hours; full effect at 1-2 weeks (long half-life) (1) · Effects accumulate over weeks; assess at 8 weeks (1) · Glycosuria within hours; HbA1c effect at 12 weeks; CV/renal benefits over months (1) · LDL lowering within 2 weeks (1) · Postprandial glucose effect within days; HbA1c by 12 weeks (1) · ~30 min (1)

24 hours (5) · 4 hours (IR); 12 hours (ER) (1) · 6 h (immediate-release); ~11 h (extended-release) (1) · Continuous daily dosing (1) · ~7-8 hours (1)

11-13 h (immediate-release); 11-16 h (extended-release) (1) · 2 hours (parent); 6-9 hours for active carboxylic acid metabolite EXP3174'"`UNIQ--ref-000000BC-QINU`"' (1) · 30-50 hours'"`UNIQ--ref-00000078-QINU`"' (1) · ~1 hour'"`UNIQ--ref-00001050-QINU`"' (1) · ~11 h (1) · ~12.4 hours'"`UNIQ--ref-00000765-QINU`"' (1) · ~12.9 hours'"`UNIQ--ref-00000552-QINU`"' (1) · ~17-19 hours (longer than daridorexant) (1) · ~22 hours (parent + active glucuronide)'"`UNIQ--ref-00000450-QINU`"' (1)

64-90% (oral; not affected by food)'"`UNIQ--ref-00000079-QINU`"' (1) · 80-90% oral (1) · High (oral)'"`UNIQ--ref-00001051-QINU`"' (1) · Variable (oral; rapidly conjugated to active glucuronide; food does not affect)'"`UNIQ--ref-00000451-QINU`"' (1) · ~33% (1) · ~33% (extensive first-pass via CYP2C9 and CYP3A4)'"`UNIQ--ref-000000BD-QINU`"' (1) · ~44% (1) · ~78% (oral; high-fat meal modestly reduces but is not clinically significant)'"`UNIQ--ref-00000553-QINU`"' (1) · ~87% (oral)'"`UNIQ--ref-00000766-QINU`"' (1)

'''Contraindicated in pregnancy''' (all trimesters); fetal renal injury, oligohydramnios, hypocalvaria, hypotension. Stop on detection'"`UNIQ--ref-000000BE-QINU`"' (1) · Avoid in second and third trimesters; fetal SGLT2 inhibition disrupts kidney development.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Category D'"`UNIQ--ref-0000006C-QINU`"' (1) · Generally considered acceptable.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Limited data; avoid (1) · Limited data; case series and registries suggest no major teratogenicity but other antihypertensives (labetalol, nifedipine) are typically preferred.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Limited data; generally avoided particularly in combination with statin.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Limited data; switch to insulin where feasible.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Not indicated; pregnancy effects unknown (1)

OTC in US (1) · Rx, Schedule IV (US) (1) · Rx-only in US (REMS program) (1) · Schedule IV (US) (1) · [[USLegal:Prescription only|Rx-only]] in US (5)

Showing below up to 9 results in range #1 to #9.

A

L

S

Sitagliptin